Valuation: Assembly Biosciences, Inc.

Market Cap 531M 466M 430M 396M 747M 51.23B 759M 5.15B 2.02B 25.07B 2B 1.95B 86.37B P/E 2026 *
-23.1x
P/E 2027 * -8.74x
Enterprise Value 531M 466M 430M 396M 747M 51.23B 759M 5.15B 2.02B 25.07B 2B 1.95B 86.37B EV / Sales 2026 *
11.7x
EV / Sales 2027 * 16.5x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-6.53%
1 week-8.54%
Current month-8.81%
1 month+2.54%
3 months-14.30%
6 months-14.67%
Current year-26.32%
1 week 24.98
Extreme 24.98
28.15
1 month 24.01
Extreme 24.01
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
6/17/26 A Sell

Chief Financial Officer

-29 0.0002%
6/4/26 A Free

Director

8,000 0.0514%
6/4/26 A Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-6.53%-8.54%+34.15%+88.14% 531M
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-3.47%+370.99%+567.62% 39.58B
-0.46%+3.98%+5.44%+60.79% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-6.91% - - 16.21B
-1.82%-1.91%+69.28%+112.51% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%-0.92%+15.77%-32.78% 13.02B
Average -1.74%-0.37%+59.79%+93.07% 24.42B
Weighted average by Cap. -1.01%-0.38%+75.82%+117.58%

Financials

2026 *2027 *
Net sales 45.47M 39.85M 36.84M 33.88M 63.93M 4.38B 64.95M 441M 173M 2.15B 171M 167M 7.39B 32.25M 28.27M 26.13M 24.03M 45.34M 3.11B 46.07M 312M 122M 1.52B 121M 118M 5.24B
Net income -20.46M -17.94M -16.58M -15.25M -28.77M -1.97B -29.23M -198M -77.71M -965M -76.84M -75.16M -3.33B -56.38M -49.42M -45.68M -42.01M -79.26M -5.44B -80.54M -546M -214M -2.66B -212M -207M -9.16B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
20/07/26 $25.06 -6.53% 112,684
17/07/26 $26.81 +3.75% 312,835
16/07/26 $25.84 -3.33% 309,430
15/07/26 $26.73 -0.11% 124,814
14/07/26 $26.76 -0.74% 104,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.81USD
Average target price
50.00USD
Spread / Average Target
+86.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock